TABLE 1.
Mean FICI values of exebacase used in addition to antibiotics in CAMHB-HSD
| Designationb | Resistance | FICA scores with:a
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAP | VAN | NAF | OXA | CFZ | TLV | AZM | CLI | GEN | LNZ | LVX | SXT | ||
| ATCC BAA-1718 | MSSA | 0.500 | 0.250 | 0.375 | 0.500 | 0.250 | 0.500 | 0.375 | 0.500 | 1.031 | 0.500 | 1.000 | 0.508 |
| NRS 107 | MSSA | 0.500 | 0.500 | 0.500 | 0.375 | 0.500 | 0.500 | 0.312 | 0.375 | 0.508 | 0.750 | 0.516 | 1.031 |
| NRS 143 | MSSA | 0.500 | 0.500 | 0.500 | 0.500 | 0.750 | 0.500 | 0.312 | 0.500 | 1.031 | 0.503 | 1.000 | 1.031 |
| NRS 112 | MSSA | 0.750 | 0.250 | 0.500 | 0.312 | 0.500 | 0.250 | 0.500 | 0.375 | 1.031 | 0.625 | 1.031 | 0.625 |
| NRS161 | MSSA | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.750 | 0.500 | 0.625 | 0.750 |
| NRS111 | MSSA | 0.500 | 0.625 | 0.250 | 0.375 | 0.500 | 0.500 | 0.375 | 0.500 | 0.625 | 0.375 | 1.000 | 0.750 |
| ATCC 29213 | MSSA | 0.375 | 0.500 | 0.312 | 0.312 | 0.500 | 0.750 | 0.500 | 0.375 | 1.031 | 0.625 | 0.750 | 0.516 |
| ATCC 49521 | MSSA | 0.500 | 0.500 | 0.375 | 0.500 | 0.500 | 0.500 | 0.500 | 0.375 | 0.563 | 0.500 | 0.750 | 1.031 |
| JMI 2559 | MSSA | 0.375 | 0.500 | 0.250 | 0.315 | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | 0.625 | 0.563 | 1.031 |
| JMI 3126 | MSSA | 0.500 | 0.625 | 0.250 | 0.375 | 0.500 | 0.625 | 0.375 | 0.500 | 0.500 | 0.625 | 1.031 | 1.031 |
| NRS 271 | MRSA | 0.254 | 0.500 | 0.250 | 0.563 | 0.500 | 0.500 | 0.313 | 0.375 | 1.063 | 0.531 | 0.625 | 1.031 |
| NRS 100 | MRSA | 0.375 | 0.500 | 0.313 | 0.500 | 0.500 | 0.500 | 0.313 | 0.375 | 0.375 | 0.500 | 1.031 | 0.750 |
| ATCC 43300 | MRSA | 0.500 | 0.375 | 0.375 | 0.375 | 0.313 | 0.500 | ND | 1.031 | 1.031 | 0.750 | 1.031 | 0.531 |
| ATCC BAA-44 | MRSA | 0.500 | 0.500 | 0.375 | 0.375 | 0.375 | 1.031 | 0.375 | 0.500 | 1.031 | 0.750 | 0.500 | 0.750 |
| CAIRD 456 | MRSA | 0.500 | 0.500 | 0.375 | 0.313 | 0.313 | 0.500 | 0.500 | 0.250 | 0.500 | 0.500 | 0.563 | 0.750 |
| JMI 227 | MRSA | 0.500 | 0.281 | 0.375 | 0.375 | 0.500 | 0.500 | 0.500 | 0.375 | 0.508 | 0.625 | 1.000 | 0.750 |
| JMI 1280 | MRSA | 0.375 | 0.313 | 0.500 | 0.156 | 0.188 | 0.750 | ND | 0.500 | 1.000 | 0.500 | 1.000 | 1.000 |
| JMI 4789 | MRSA | 0.375 | 0.281 | 0.375 | 0.375 | 0.500 | 0.500 | 0.375 | 0.375 | 0.508 | 0.500 | 0.750 | 0.504 |
| MW2 | MRSA | 0.500 | 0.515 | 0.250 | 0.375 | 0.500 | 1.031 | 0.375 | 0.500 | 0.750 | 0.625 | 1.000 | 1.031 |
| ATCC 33591 | MRSA | 0.500 | 0.500 | 0.500 | 0.500 | 0.250 | 0.504 | ND | 0.500 | 1.000 | 0.375 | 1.000 | 0.508 |
a
Mean FICI values were calculated based on the individual FICI values observed by row over at least 3 consecutive rows on each checkerboard panel. The FICI values are consistent with the following interactions: synergy, ≤0.5 (bold); additivity, >0.5 to ≤1 (italic); no interaction (indifference) >1 to ≤4 (shaded); antagonism, >4. ND, not determined; DAP, daptomycin; VAN, vancomycin; NAF, nafcillin; OXA, oxacillin; CFZ, cefazolin; TLV, telavancin; AZM, azithromycin; CLI, clindamycin; GEN, gentamicin; LNZ, linezolid; LVX, levofloxacin; SXT, sulfamethoxazole-trimethoprim.
b
The bacterial strains are described in Table S2 in the supplemental material.